UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 10, 2017

athenahealth, Inc.
(Exact name of registrant as specified in its charter)
Delaware
 
001-33689
 
04-3387530
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

 
311 Arsenal Street, Watertown, MA 02472
 
 
(Address of principal executive office, including zip code)
 

Registrant’s telephone number, including area code: 617-402-1000
________________________________________________________________________________

(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[   ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[   ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[   ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[   ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐






Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 10, 2017, athenahealth, Inc. (the “Company”) entered into a separation agreement (the “Separation Agreement”) with Karl Stubelis pursuant to which he will step down from his positions as senior vice president, chief financial officer, chief accounting officer, and treasurer of the Company to pursue other opportunities. To help ensure a smooth transition, Mr. Stubelis will continue to support the Company through the reporting of the Company’s 2017 second quarter results and will continue to be employed by the Company on a full-time basis through July 21, 2017 (the “Separation Date”).
The Separation Agreement, which supersedes the terms of the Employment Agreement between the Company and Mr. Stubelis, dated May 19, 2016, provides that the Company will continue to pay Mr. Stubelis his current base salary for a period of twelve (12) months following the Separation Date and will also permit certain of Mr. Stubelis’s restricted stock units, which represent a right to acquire 4,500 shares of the Company’s common stock, to continue to vest through their next scheduled vesting date.
On July 13, 2017, the board of directors (the “Board”) of the Company appointed John A. “Jack” Kane, 64, a member of the Board since July 2007 and current chair of the Board’s audit committee, to serve as interim chief financial officer, effective July 21, 2017. Mr. Kane will serve as the Company’s principal financial officer and principal accounting officer in his role as interim chief financial officer. During his service as interim chief financial officer, Mr. Kane will remain on the Board but will step down as chair of the audit committee. The Company expects to provide compensation to Mr. Kane in connection with his appointment as interim chief financial officer. The terms of such compensation, once finalized, will be described in an amendment to this Current Report on Form 8-K.
Previously, Mr. Kane served as chief financial officer and treasurer of IDX Systems Corporation (“IDX”), a healthcare software technology company, from October 1984 until it was acquired by General Electric Healthcare in January 2006, after which he served as a vice president of General Electric Healthcare from January 2006 to December 2006. While at IDX, Mr. Kane guided the company through more than a dozen acquisitions and at various times managed the finance, facilities, legal, human resources, and information systems functions for the company. Since his retirement in 2006, Mr. Kane has served as a director of several private organizations, and also served as a director of Merchants Bancshares, Inc. from 2005 to 2014. Prior to his employment with IDX, Mr. Kane worked as an audit manager at Ernst & Young LLP in Boston. Mr. Kane received his B.S. and a Master of Accountancy from Brigham Young University. 
A copy of the press release issued by the Company on July 14, 2017 regarding the transition of Mr. Stubelis and appointment of Mr. Kane is attached hereto as Exhibit 99.1.
The foregoing summary of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01.    Financial Statements and Exhibits.
(d)     Exhibits .
Exhibit No.
 
Description
10.1
 
Separation Agreement between athenahealth, Inc. and Karl Stubelis, dated July 10, 2017.
99.1
 
Press release issued by athenahealth, Inc. on July 14, 2017.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
athenahealth, Inc.
 
 
(Registrant)

July 14, 2017
 
/s/ Dan Haley
 
 
Dan Haley
 
 
Senior Vice President, General Counsel and Secretary






EXHIBIT INDEX
Exhibit No.
 
Description
10.1
 
Separation Agreement between athenahealth, Inc. and Karl Stubelis, dated July 10, 2017.
99.1
 
Press release issued by athenahealth, Inc. on July 14, 2017.





Exhibit 10.1


EX101LOGOA01.JPG



Daniel Haley
Senior Vice President and
General Counsel
athenahealth, Inc.
311 Arsenal Street
Watertown, MA 02472
dhaley@athenahealth.com
                                

July 10, 2017

BY EMAIL (kstubelis@athenahealth.com)
Karl Stubelis
[address omitted]

Dear Karl:

The purpose of this letter agreement (this “ Agreement ”) is to confirm the terms of the remainder of your employment with athenahealth, Inc. (the “ Company ”) and your separation from the Company. If the terms of this Agreement are acceptable to you, please sign, date and return it to me within twenty-one (21) days following the date you receive it. You may revoke this Agreement at any time during the seven-day period immediately following the date of your signing by notifying me in writing of your revocation within that period. If you revoke this Agreement as described in the preceding sentence, then this Agreement shall not take effect. If you do not revoke this Agreement, then, on the eighth day following the date that you signed it, this Agreement shall take effect as a legally binding agreement between you and the Company on the basis set forth herein.

1. Transition Period and Separation Date.

(a)      As we have discussed, effective as of July 10, 2017 (the “ Transition Date ”) through the date that your employment terminates (the “ Separation Date ”), you will continue to be employed by the Company on a full-time basis. Provided that you comply in full with your obligations hereunder, it is expected that the Separation Date will be July 21, 2017. The period beginning on the Transition Date and concluding on the Separation Date is hereinafter referred to as the “ Transition Period .”

(b)      During the Transition Period, you will continue to receive your base salary, payable at the rate in effect as of the date hereof, and to participate in all employee benefit plans of the Company in accordance with the terms of those plans.

1



Exhibit 10.1


(c)      During the Transition Period, you will continue to perform your regular duties as the Company’s Chief Financial Officer, and any other duties assigned to you from time to time by the Chief Executive Officer of the Company or his designee, and will assist with the smooth transition of your duties and responsibilities to the Company’s designees. You agree that, during the Transition Period, you will continue to devote your best professional efforts to the Company, and that you will continue to abide by all Company policies and procedures as in effect from time to time. You will not incur any business expenses, except as necessary for the performance of your regular job duties in the ordinary course of business, during the Transition Period without the advance approval of the Chief Executive Officer or his designee. During the Transition Period, except as necessary for the performance of your regular job duties in the ordinary course of business, you shall have no authority to, and you shall not attempt to, take any action on behalf of the Company, bind the Company to any third party, or hold yourself out as a representative or agent of the Company, without the prior written consent of the Chief Executive Officer or his designee.
(d)      The Company may terminate your employment at any time during the Transition Period upon notice to you. If the Company terminates your employment for Cause (as defined herein), you will not be eligible to receive the severance benefits described in Section 3 hereof, but this Agreement shall otherwise remain in full force and effect. For purposes of this Agreement, Cause , as determined by the Company in its reasonable judgment exercised in good faith, means (i) your failure to perform, or gross negligence in the performance of, your duties and responsibilities to the Company or any of its Affiliates; (ii) your material breach of this Agreement or any other agreement between you and the Company or any of its Affiliates; (iii) your commission of a felony or other crime involving moral turpitude; or (iv) other conduct by you that is harmful to the business interests or reputation of the Company or any of its Affiliates. For purposes of this Agreement, “ Affiliates ” means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by management authority, equity interest or otherwise.

(e)      For the avoidance of doubt, if you voluntarily terminate your employment with the Company prior to July 21, 2017, then you shall not be eligible to receive the severance benefits described in Section 3 hereof, but this Agreement shall otherwise remain in full force and effect.

2.      Final Salary and Vacation Pay. You will receive pay for all work you performed for the Company through the Separation Date, to the extent not previously paid, as well as pay, at your final base rate of pay, for any vacation days you earned but had not used as of the Separation Date, determined in accordance with Company policy and as reflected on the books of the Company. You will receive the payments described in this Section 2 regardless of whether or not you sign this Agreement.


2



Exhibit 10.1


3.      Severance Benefits. In consideration of your acceptance of this Agreement and subject to your meeting in full your obligations under it, including without limitation your obligation to execute a post-employment general release and waiver of claims in the form attached hereto as Exhibit A (the “ Release ):
(a)      the Company will continue to employ you during the Transition Period on the terms described in Section 1 hereof;

(b)      the Company will continue to pay you your salary, at your final base rate of pay, for a period of twelve (12) months following the Separation Date; and

(c)      the Company will permit certain of your restricted stock units to continue to vest through their next scheduled vesting date, as shown on Exhibit B hereto. For the avoidance of doubt, any other restricted stock units that are not vested on the Separation Date and do not continue to vest pursuant to this Section 3(c) shall terminate and be forfeited on the Separation Date. Further, all of your Performance Stock Units (“ PSUs ”), including without limitation the PSUs granted to you in March 2017, shall terminate and be forfeited on the Separation Date. Other than the continued vesting described in this Section 3(c), your restricted stock units will be administered in accordance with the terms of their original grants.
The payments described in Section 3(b) will be made in the form of salary continuation, and will begin on the next regular Company payday which is at least seven (7) business days following both the effective date of the Release and the date that the Release, signed by you, is received by the Company. The first payment will be retroactive to the day following the Separation Date.

4.      Acknowledgement of Full Payment and Withholding.
(a)      You acknowledge and agree that the payments provided under Section 2 of this Agreement are in complete satisfaction of any and all compensation due to you from the Company, whether for services provided to the Company or otherwise, through the Separation Date and that, except as expressly provided under this Agreement, no further compensation or benefits are owed or will be provided to you.
(b)      All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law and all other lawful deductions authorized by you.

3



Exhibit 10.1


5.      Status of Employee Benefits, Paid Time Off, Expenses, and Equity.
(a)      Except for any right you may have to continue your participation and that of your eligible dependents in the Company’s medical, dental, and vision plans under the federal law known as “COBRA,” your participation in all employee benefit plans of the Company will end as of the Separation Date, in accordance with the terms of those plans. You acknowledge that you will not continue to earn paid time off or other similar benefits after the Separation Date. You will receive information about your COBRA continuation rights under separate cover.

(b)      Within two (2) weeks following the Separation Date, you must submit your final expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement, and, in accordance with Company policy, reasonable substantiation and documentation for the same. The Company will reimburse you for your authorized and documented expenses within thirty (30) days of receiving such statement pursuant to its regular business practice.
(c)      Except as otherwise provided in Section 3(c) of this Agreement, your rights and obligations with respect to any stock options, restricted stock units, or other forms of equity interest granted to you by the Company during or in connection with your employment shall be governed by the applicable equity plan(s) and any agreements or other requirements applicable to those options, restricted stock units, or other equity interests. Except as otherwise provided in Section 3(c) of this Agreement, all stock options, restricted stock units, or other equity interests which are unvested as of the Separation Date will be cancelled as of that date.
6.      Continuing Obligations and Non-Disparagement.
(a)      You acknowledge that, during the Transition Period and following the Separation Date, you continue to be bound by your obligations under the Employment Agreement between you and the Company, which you signed on May 19, 2016 (the “ Employment Agreement ”), that survive the termination of your employment by the terms thereof (the “ Continuing Obligations ”).
(b)      For the avoidance of doubt, nothing contained in this Agreement, the Release, or the Continuing Obligations limits or in any other way affects your communicating or cooperating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity. You will not be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret in confidence to a government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or for disclosing a trade secret in a complaint or other document filed in a lawsuit or other proceeding, so long as such filing is made under seal. You may disclose a trade secret to your attorney in connection with filing a lawsuit for retaliation for reporting a suspected violation of law, and you may use

4



Exhibit 10.1


the trade secret information in that court proceeding, so long as any document containing the trade secret is filed under seal; and you may not otherwise disclose the trade secret, except pursuant to court order. Nothing in this Agreement, the Release, or the Continuing Obligations requires you to obtain prior authorization from the Company before engaging in any conduct described in this Section 6(b), or to notify the Company that you have engaged in any such conduct. 
(c)      Subject to Sections 6(b) and 9(b) of this Agreement, you agree that you will never disparage or criticize the Company, its Affiliates, their business, their management, or their products or services, and that you will not otherwise do or say anything that could disrupt the good morale of employees, clients, or prospects of the Company or any of its Affiliates or harm the interests or reputation of the Company or any of its Affiliates. The Company agrees to instruct its Chief Executive Officer and his direct reports to never disparage or criticize you, and to instruct its Chief Executive Officer and his direct reports otherwise not to do or say anything with the intent of harming your interests or reputation.

(d)      In signing this Agreement, you represent and warrant that, since the Transition Date, you have complied with all of your obligations under this Agreement, including without limitation under this Section 6, and the Continuing Obligations.

7.      Return of Company Documents and Other Property. In signing this Agreement, you agree that, during the Transition Period, you will only use or access documents, materials, information, property, or systems of the Company and its Affiliates to the extent necessary to perform the job duties described in Section 1(c) of this Agreement, or with the prior written consent of the Chief Executive Officer or his designee. You further represent and warrant that you will return to the Company upon the Separation Date, or immediately upon such other date as the Company may demand, any and all documents, materials and information (in any form) related to the business of the Company and its Affiliates (present or otherwise), and all keys, access cards, credit cards, computer hardware and software, telephones and all other property of the Company or any of its Affiliates in your possession or control. Further, you represent and warrant that you will not make or retain following the Separation Date any copy or derivation of any documents, materials or information (in any form) of the Company or any of its Affiliates. Recognizing that your employment with the Company will end on the Separation Date, you represent and warrant that you will not, after the Separation Date, for any purpose, attempt to access or use any information, computer, or computer network or system of the Company or any of its Affiliates, including without limitation the electronic mail system. Further, you represent and warrant that you have disclosed to the Company all passwords necessary, desirable, or helpful to obtain access to all information which you have password-protected on any computer equipment, network, or system of the Company or any of its Affiliates.


5



Exhibit 10.1


8.      Employee Cooperation. You agree to cooperate with the Company and its Affiliates hereafter with respect to all matters arising during or related to your employment, including but not limited to all matters in connection with any governmental investigation, litigation or regulatory or other proceeding which may have arisen or which may arise following the signing of this Agreement. The Company will reimburse your out-of-pocket expenses incurred in complying with Company requests hereunder, provided such expenses are authorized by the Company in advance.

9.      General Release of Claims.
(a)      In exchange for the severance pay and benefits provided to you under this Agreement, to which you would not otherwise be entitled, on your own behalf and that of your heirs, executors, administrators, beneficiaries, personal representatives and assigns, you agree that this Agreement shall be in complete and final settlement of any and all causes of action, rights and claims (“ Claims ”), whether known or unknown, that you have had in the past, now have, or might now have against the Company, its Affiliates and all of their respective past, present and future directors, shareholders, officers, members, managers, general and limited partners, employees, employee benefit plans, administrators, attorneys, trustees, agents, representatives, successors and assigns, and all others connected with any of them, both individually and in their official capacities (collectively, the “ Released Parties ”). You hereby release and forever discharge the Released Parties, from any and all such Claims, including without limitation any and all Claims in any way related to, connected with or arising out of your employment or its termination, or pursuant to Title VII of the Civil Rights Act, the Americans with Disabilities Act, the Age Discrimination in Employment Act (ADEA), as amended by the Older Workers Benefit Protection Act, the Employee Retirement Income Security Act, the wage and hour, wage payment and fair employment practices laws and statutes of the Commonwealth of Massachusetts and any other state or states in which you have performed work for the Company (each as amended from time to time), any public policy, statutory, contract, tort, or common law, any basis for recovering costs, fees, or other expenses including attorneys’ fees, and/or any other federal, state or local law, regulation or other requirement. You acknowledge and agree that this is a general, and not a limited, release.
(b)      Nothing in this Agreement shall be construed to prohibit or prevent you from filing a charge with or participating in any investigation or proceeding conducted by any federal, state, or local agency, provided, however, that you hereby agree to waive your right to recover monetary damages or other individual relief from the Company or any of its Affiliates in any charge, complaint or lawsuit filed by you or by anyone else on your behalf by, with or before any such agency.
(c)      If any claim is not subject to release, to the extent permitted by law, you hereby waive any right or ability to be a class or collective action representative or to otherwise

6



Exhibit 10.1


participate in any putative or certified class, collective or multi-party action or proceeding based on such a claim in which any of the Released Parties is a party.

(d)      This Agreement, including the general release of claims set forth in Section 9(a) above and the general release of claims attached hereto as Exhibit A, creates legally binding obligations and the Company and its Affiliates therefore advise you to consult an attorney before signing this Agreement and the Release. In signing this Agreement, you give the Company and its Affiliates assurance that you have signed it voluntarily and with a full understanding of its terms; that you have had sufficient opportunity of not less than twenty-one (21) days, before signing this Agreement, to consider its terms and to consult with an attorney, if you wished to do so, or to consult with your immediate family members or your legal or tax advisors; and that, in signing this Agreement, you have not relied on any promises or representations, express or implied, that are not set forth expressly in this Agreement.

(e)      You agree to sign the Release by the later of seven (7) days following the Separation Date and twenty-one (21) days following the date hereof (and in no event before the Separation Date), and not to revoke the Release after you sign it. You further agree that a signed and unrevoked Release is an express condition to your receipt and retention of the severance benefits described in Section 3 above. Failure to sign the Release within this time period will result in a forfeiture of the severance benefits described herein.

10.      Section 409A. This Agreement is intended to comply with the requirements of Section 409A of the Internal Revenue Code (the “ Code ”) and shall be interpreted and construed consistently with such intent. The payments to you pursuant to this Agreement are also intended to be exempt from Section 409A of the Code to the maximum extent possible. Each payment made under this Agreement shall constitute a “separately identified” amount within the meaning of Treasury Regulation § 1.409A-2(b)(2). Notwithstanding anything in this Agreement to the contrary, in the event that any amounts payable (or benefits provided) under this Agreement are subject to the provisions of Section 409A of the Code, to the extent determined necessary, the parties agree to amend this Agreement in the least restrictive manner necessary to avoid imposition of any additional tax or income recognition on you under Section 409A of the Code, the final Treasury Regulations and other Internal Revenue Service guidance thereunder (“ 409A Penalties ”); provided, however, that in no event shall the Company be responsible for any 409A Penalties that arise in connection with any amounts payable under this Agreement. In addition, to the extent necessary to comply with Section 409A of the Code, references to Separation Date (and similar phrases) in this Agreement shall be interpreted in a manner that is consistent with the term “separation from service” under Section 409A(a)(2)(A)(i) of the Code and final Treasury Regulations and other Internal Revenue Service guidance thereunder. Notwithstanding any provision of this Agreement to the contrary, if you are a “specified employee” of the Company (as defined in Section 409A of the Code), amounts subject to Code Section 409A that

7



Exhibit 10.1


would otherwise have been paid to or on behalf of you under the foregoing provisions of this Agreement during the six-month period immediately following the Separation Date shall be paid on the first regular payroll date immediately following the six-month anniversary of the Separation Date.

11.      Nonadmission of Wrongdoing. You agree that neither this Agreement nor the furnishing of the consideration for this Agreement shall be deemed or construed at any time for any purpose as an admission by the Released Parties of wrongdoing or evidence of any liability or unlawful conduct of any kind.

12.      Employee Representations. In signing this Agreement, you represent and agree that, as of the date you sign this Agreement:

(a)      You have been paid or provided with all compensation, wages, bonuses, commissions, and/or benefits which are due and payable to you through such date;
(b)      You have been granted any leave or accommodation to which you were entitled under the Family and Medical Leave Act, the Americans with Disabilities Act, or related or similar state or local leave or disability accommodation laws;
(c)      You have no known workplace injuries or occupational diseases;
(d)      You have not divulged any proprietary, confidential or privileged information of the Company and will continue to maintain the confidentiality of such information consistent with Company policy, the Continuing Obligations, this Agreement, and your legal obligations;
(e)      You have not been retaliated against for reporting any allegations of wrongdoing by the Company, its Affiliates or their respective officers or employees, including any allegations of corporate fraud; and
(f)      All of the Company’s decisions regarding your employment, the terms and conditions of your employment, and your pay and benefits through the Separation Date were not discriminatory based on age, disability, race, color, sex, religion, national origin or any other classification protected by applicable law, and were not retaliatory.
13.      Miscellaneous.
(a)      This Agreement constitutes the entire agreement between you and the Company, and supersedes all prior and contemporaneous communications, agreements and understandings, whether written or oral, with respect to your employment, its termination and all related matters, including without limitation the terms of Section 7(d) of the Employment Agreement, and excluding only (i) the Continuing Obligations, (ii) any loan or other amount you

8



Exhibit 10.1


owe to the Company, (iii) the most recent indemnification agreement between you and the Company, and (iv) your obligations with respect to the securities of the Company, all of which shall remain in full force and effect in accordance with their terms.
(b)      This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and the General Counsel of the Company or his expressly authorized designee. The captions and headings in this Agreement are for convenience only, and in no way define or describe the scope or content of any provision of this Agreement.
(c)      You agree that, any modifications, material or otherwise, made to this Agreement, do not restart or affect in any manner the original consideration period of 21 days.

(d)      The obligation of the Company to make payments or provide benefits to you or on your behalf under this Agreement, and your right to retain the same, is expressly conditioned upon your continued full performance of your obligations under this Agreement and the Continuing Obligations.
(e)      This is a Massachusetts contract and shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to any conflict of laws principles that would result in the application of the laws of any other jurisdiction. You agree to submit to the exclusive jurisdiction of the state and federal courts of the Commonwealth of Massachusetts in connection with any dispute arising out of this Agreement.

As described on the first page of this Agreement, if the terms of this Agreement are acceptable to you, please sign, date and return it to me within twenty-one (21) days of the date you receive it. You may revoke this Agreement at any time during the seven-day period immediately following the date of your signing by notifying me in writing of your revocation within that period. If you revoke this Agreement as described in the preceding sentence, then this Agreement shall not take effect. If you do not revoke this Agreement, then, on the eighth day following the date that you signed it, this Agreement shall take effect as a legally binding agreement between you and the Company on the basis set forth above.

9



Exhibit 10.1


I want to thank you for all of your efforts on behalf of the Company and to wish you well in your future endeavors.

Sincerely,
ATHENAHEALTH, INC.


By:     /s/ Dan Haley __________________________
Daniel Haley,
Senior Vice President and General Counsel
Accepted and agreed:


Signature: /s/ Karl Stubelis _______________
Karl Stubelis

Date: __ July 10, 2017 ___________________

10



Exhibit 10.1



Exhibit A
Post-Employment General Release and Waiver of Claims

For and in consideration of certain benefits to be provided to me under the letter agreement between me and athenahealth, Inc. (the “ Company ”), dated as of July 10, 2017 (the “ Agreement ”), which are conditioned on my signing this General Release and Waiver of Claims (this “ Release of Claims ”), and to which I am not otherwise entitled, and other good and valuable consideration, the receipt and sufficiency of which I hereby acknowledge, on my own behalf and on behalf of my heirs, executors, administrators, beneficiaries, representatives, successors and assigns, and all others connected with or claiming through me, I hereby release and forever discharge the Company and its Affiliates (as defined in the Agreement), and all of their respective past, present and future officers, directors, shareholders, members, managers, general and limited partners, employees, employee benefit plans, administrators, attorneys, trustees, agents, representatives, consultants, successors and assigns, and all those connected with any of them, in their official and individual capacities (collectively, the “ Released Parties ”), from any and all causes of action, rights and claims, whether known or unknown, which I have had in the past, now have or might now have against the Released Parties, or any of them, including without limitation any and all causes of action, rights and claims in any way related to, connected with or arising out of my employment and/or other relationship with the Company or any of its Affiliates, or the termination thereof, or pursuant to Title VII of the Civil Rights Act, the Americans With Disabilities Act, the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, the Employee Retirement Income Security Act, the wage and hour, wage payment and fair employment practices laws of the Commonwealth of Massachusetts and any other state in which I have provided services to the Company (each as amended from time to time), any public policy, contract, tort or common law, any basis for recovering costs, fees, or other expenses including attorneys’ fees, and/or any other federal, state or local law, regulation or other requirement (collectively, the “ Claims ”) through the date that I sign this Release of Claims, and I hereby waive all such Claims. I acknowledge and agree that this is a general, and not a limited, release.

I understand that nothing in this Agreement shall be construed to prohibit or prevent me from filing a charge with or participating in any investigation or proceeding conducted by any federal, state, or local agency, provided, however, that I hereby agree to waive my right to recover monetary damages or other individual relief from the Company or any of its Affiliates in any charge, complaint or lawsuit filed by me or by anyone else on my behalf by, with or before any such agency.
If any claim is not subject to release, to the extent permitted by law, I hereby waive any right or ability to be a class or collective action representative or to otherwise participate in any

11



Exhibit 10.1


putative or certified class, collective or multi-party action or proceeding based on such a claim in which any of the Released Parties is a party.

In signing this Release of Claims, I represent that, as of the date I sign this Release of Claims:

(a)      I have been paid or provided with all compensation, wages, bonuses, commissions, and/or benefits which are due and payable to me;
(b)      I have been granted any leave or accommodation to which I was entitled under the Family and Medical Leave Act, the Americans with Disabilities Act, or related or similar state or local leave or disability accommodation laws;
(c)      I have no known workplace injuries or occupational diseases;
(d)      I have not divulged any proprietary, confidential or privileged information of the Company and I will continue to maintain the confidentiality of such information consistent with Company policy, the Continuing Obligations, the Agreement, and my legal obligations;
(e)      I have not been retaliated against for reporting any allegations of wrongdoing by the Company, its Affiliates or their respective officers or employees, including any allegations of corporate fraud; and
(f)      All of the Company’s decisions regarding my employment, the terms and conditions of my employment, and my pay and benefits through the Separation Date (as defined in the Agreement) were not discriminatory based on age, disability, race, color, sex, religion, national origin or any other classification protected by law, and were not retaliatory.
I acknowledge that this Release of Claims creates legally binding obligations, and that the Company hereby advises me to consult an attorney before signing it. I further acknowledge that I may not sign this Release of Claims prior to the Separation Date. In signing this Release of Claims, I give the Company assurance that I have signed it voluntarily and with a full understanding of its terms; that I have had sufficient opportunity of not less than twenty-one (21) days before signing this Release of Claims to consider its terms and to consult with an attorney, if I wished to do so, or to consult with my immediate family members or my legal or tax advisors; and that I have not relied on any promises or representations, express or implied, that are not set forth expressly in this Release of Claims. I understand that I will have seven (7) days after signing this Release of Claims to revoke my signature, and that, if I intend to revoke my signature, I must do so in writing addressed and delivered to the Company’s General Counsel prior to the end of the seven (7)-day revocation period. I understand that, if I revoke this Release of Claims as described in the preceding sentence, then this Release of Claims shall not take effect. I understand that this Release of Claims will become effective upon the eighth (8th) day following the date that I sign it, provided that I do not revoke my acceptance in accordance with this paragraph.

12



Exhibit 10.1




13



Exhibit 10.1


Accepted and agreed:


Signature:    ____________________________
Karl Stubelis
    
Date:     ____________________________

14



Exhibit 10.1



Exhibit B
Vesting of Restricted Stock Units

Award No.
Vest Date
Number of RSUs Vesting
5655
9/3/2017
1,375
11731
6/1/2018
3,125
 
TOTAL
4,500


15


Exhibit 99.1

EX101LOGOA01.JPG


athenahealth Announces Chief Financial Officer Transition
 
John A. Kane Appointed Interim Chief Financial Officer

Karl Stubelis Steps Down to Pursue Other Opportunities

Company Reaffirms Fiscal Year 2017 Guidance


WATERTOWN, Mass. – July 14, 2017 – athenahealth, Inc. (NASDAQ: ATHN), a leading provider of network-enabled services for hospital and ambulatory clients nationwide, today announced that John A. “Jack” Kane, a member of the athenahealth Board of Directors and current chair of the Board’s Audit Committee, will serve as interim chief financial officer, effective July 21, 2017. Karl Stubelis is stepping down as chief financial officer to pursue other opportunities. To help ensure a smooth transition, Mr. Stubelis will continue to support the Company through the reporting of athenahealth’s 2017 second quarter results. athenahealth has initiated a search to identify a permanent CFO and has retained DHR International to assist in the process.

Jonathan Bush, chairman and chief executive officer of athenahealth, said, “This CFO transition reflects our commitment to ensuring that athenahealth has world-class leaders to support the Company and our increased scale and scope. We intend to focus our CFO search on leaders who bring a record of operating discipline and value-creating capital allocation. I look forward to working closely with the athenahealth Board, especially Jack Kane and Tom Szkutak, former CFO of Amazon, to identify the best individual for the role.”

“Jack’s knowledge of athenahealth and his experience serving as the CFO of another public healthcare technology company make him well suited to serve as interim CFO during this transition,” Mr. Bush continued. “We are pleased to benefit from his expertise and counsel in this expanded role.”

Mr. Kane said, “I look forward to working closely with the athenahealth team as I take on these additional responsibilities. We share Jonathan’s confidence in athenahealth and his focus on identifying a CFO who can serve as a strong partner to the senior management team in guiding the Company’s success.”

Mr. Bush concluded, “I want to thank Karl for his contributions and wish him well in his future endeavors.”

In connection with today’s announcement, the athenahealth Board intends to reconstitute its Audit Committee and expects to appoint Tom Szkutak as chair, effective with Mr. Kane’s appointment as interim CFO.




Exhibit 99.1


2017 Guidance Reaffirmed

athenahealth today reaffirmed its fiscal year 2017 guidance, previously provided on April 27, 2017:

For the Fiscal Year Ending December 31, 2017
Forward-Looking Guidance
Financial Measures
 
 
GAAP Total Revenue
 
$1,210 million - $1,250 million
GAAP Operating Income
 
$36 million - $46 million
Non-GAAP Adjusted Operating Income
 
$120 million - $140 million
Financial Metric
 
 
Annual Bookings
 
$350 million - $400 million

About John A. Kane

John A. “Jack” Kane has served as a member of the athenahealth Board of Directors since July 2007. Mr. Kane served as chief financial officer and treasurer of IDX Systems Corporation (“IDX”), a healthcare software technology company, from October 1984 until it was acquired by General Electric Healthcare in January 2006, after which he served as a vice president of General Electric Healthcare from January 2006 to December 2006. While at IDX, Mr. Kane guided the company through more than a dozen acquisitions and at various times managed the finance, facilities, legal, human resources, and information systems functions for the company. Since his retirement in 2006, Mr. Kane has served as a director of several private organizations, and also served as a director of Merchants Bancshares, Inc. (MBVT) from 2005 to 2014. Prior to his employment with IDX, Mr. Kane worked as an audit manager at Ernst & Young LLP in Boston. Mr. Kane received his B.S. and a Master of Accountancy from Brigham Young University.

About athenahealth, Inc.

athenahealth partners with hospital and ambulatory clients to drive clinical and financial results. We offer medical record, revenue cycle, patient engagement, care coordination, and population health services. We combine insights from our network of 99,000 providers and 88 million patients with deep industry knowledge and perform administrative work at scale. For more information, please visit www.athenahealth.com.


Exhibit 99.1



Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding management’s expectations for future financial and operational performance and operating expenditures, expected growth, and business outlook, including our fiscal 2017 guidance; statements regarding the announced leadership transition; statements regarding our CFO search process; and statements found under our “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures for Fiscal Year 2017 Guidance” sections of this release. Forward-looking statements may be identified with words such as “will,” “may,” “expect,” “plan,” “anticipate,” “upcoming,” “believe,” “estimate,” or similar terminology, and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include: our highly competitive industry and our ability to compete effectively and remain innovative; the development of the market for cloud-based healthcare information technology services; changes in the healthcare industry and their impact on the demand for our services; our ability to maintain consistently high growth rates due to lengthening customer sales cycles; the impact of changes in our business model and structure; our ability to successfully implement operational and leadership transitions and initiatives; our ability to effectively manage our growth; our ability to protect our intellectual property; current and future litigation, including for intellectual property infringement; our dependence on third-party providers; risks and costs associated with our worldwide operations; our ability to attract and retain highly-skilled employees; our fluctuating operating results; our ability to retain our clients and maintain client revenue; our tax liability; our variable sales and implementation cycles; the timing at which we recognize certain revenue and our ability to evaluate our prospects; defects and errors in our software or services, or interruptions or damages to our systems or those of third parties on which we rely; a data security breach; limitations on our use of data; the effect of payer and provider conduct; the failure of our services to provide accurate and timely information; changing government regulation and the costs and challenges of compliance; the potential for illegal behavior by employees or subcontractors; and the price volatility of our common stock. Forward-looking statements speak only as of the date hereof and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. For additional information regarding these and other risks faced by us, refer to our public filings with the Securities and Exchange Commission (“SEC”), available on the Investors section of our website at www.athenahealth.com and on the SEC’s website at www.sec.gov.




Exhibit 99.1


athenahealth, Inc.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
TO COMPARABLE GAAP MEASURES FOR FISCAL YEAR 2017 GUIDANCE
(Unaudited, in millions, except per share amounts)

Please note that the figures presented below may not sum exactly due to rounding.

Non-GAAP Adjusted Operating Income Guidance
Set forth below is a reconciliation of our “Non-GAAP Adjusted Operating Income” and “Non-GAAP Adjusted Operating Income Margin” guidance for fiscal year 2017, which represents Non-GAAP Adjusted Operating Income as a percentage of total revenue.

 
LOW
HIGH
 
Fiscal Year Ending
December 31, 2017
Total revenue
$
1,210
 
$
1,250
 
 
 
 
GAAP operating income
$
36
 
$
46
 
 
 
 
GAAP operating income margin
3.0
%
3.7
%
 
 
 
Add: Stock-based compensation expense
60
 
70
 
Add: Amortization of capitalized stock-based compensation related to software development
2
 
2
 
Add: Amortization of purchased intangible assets
17
 
17
 
Add: Integration and transaction costs
5
 
5
 
Add: Exit costs, including restructuring (1)
 
 
Add: Gain or loss on investments (1)
 
 
 
 
 
Non-GAAP Adjusted Operating Income
$
120
 
$
140
 
 
 
 
Non-GAAP Adjusted Operating Income Margin
9.9
%
11.2
%
 
 
 
 
 

(1) We currently do not anticipate exit costs, including restructuring or gain or loss on investments during fiscal year 2017. However, if these items occur in fiscal year 2017, we would exclude these items from our Non-GAAP Adjusted Operating Income and Non-GAAP Adjusted Operating Income Margin.




Exhibit 99.1


Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with generally accepted accounting principles in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of athenahealth and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

In Q4 2016, management redefined “ Non-GAAP   Adjusted Gross Profit ” as total revenue, less cost of revenue, plus (1) stock-based compensation expense allocated to cost of revenue, (2) amortization of purchased intangible assets allocated to cost of revenue, (3) integration and transactions costs allocated to cost of revenue, and (4) exit costs, including restructuring costs allocated to cost of revenue, and “ Non-GAAP   Adjusted Gross Margin ” as Non-GAAP Adjusted Gross Profit as a percentage of total revenue. Management defines “ Service Automation Profit, ” formerly referred to as Non-GAAP Adjusted Gross Profit, as total revenue, less cost of revenue, plus (1) stock-based compensation expense allocated to cost of revenue, (2) amortization of purchased intangible assets allocated to cost of revenue, (3) integration and transaction costs allocated to cost of revenue, (4) exit costs, including restructuring costs allocated to cost of revenue, (5) amortization and depreciation expense allocated to cost of revenue, and (6) overhead expense allocated to cost of revenue, and “ Service Automation Rate, ” formerly referred to as Non-GAAP Adjusted Gross Margin, as Service Automation Profit as a percentage of total revenue. Management considers these non-GAAP financial measures and metrics to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends. Moreover, management believes that these measures and metrics enable investors and financial analysts to closely monitor and understand changes in our ability to generate income from ongoing business operations.


Management defines “
Non-GAAP   Adjusted Operating Income ” as the sum of GAAP net income (loss) before provision for (benefit from) income taxes; total other expense (income); stock-based compensation expense; amortization of capitalized stock-based compensation related to software development; amortization of purchased intangible assets; integration and transaction costs; exit costs, including restructuring costs; and gain or loss on investments; and “ Non-GAAP   Adjusted Operating Income Margin ” as Non-GAAP Adjusted Operating Income as a percentage of total revenue. Management defines “ Non-GAAP   Adjusted Net Income ” as the sum of GAAP net income (loss) before stock-based compensation expense; amortization of capitalized stock-based compensation related to software development; amortization of purchased intangible assets; integration and transaction costs; exit costs, including restructuring costs; and gain or loss on investments and any tax impact related to these preceding items; and an adjustment to the tax provision for the non-GAAP tax rate and “ Non-GAAP   Adjusted Net Income per Diluted Share ” as Non-GAAP Adjusted Net Income divided by weighted average diluted shares outstanding. Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends. Moreover, management believes that these measures enable investors and financial analysts to closely monitor and understand changes in our ability to generate income from ongoing business operations.

Management excludes or adjusts each of the items identified below from the applicable non-GAAP financial measure or metric referenced above for the reasons set forth with respect to that excluded item:

Stock-based compensation expense and amortization of capitalized stock-based compensation related to software development  — excluded because these are non-cash expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also


Exhibit 99.1


because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred.

Amortization of purchased intangible assets  — purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Integration and transaction costs  — Integration costs are the severance payments and retention bonuses for certain employees related to specific transactions. Transaction costs are costs related to strategic transactions. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Exit costs, including restructuring costs  — represents costs related to workforce reductions and to terminate certain lease or other agreements for strategic realignment purposes. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are incurred.


Gain or loss on investments  — represents gains or losses on the sales, conversions, or impairments of our investments, such as marketable securities and More Disruption Please Accelerator investments. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

Non-GAAP tax rate  — We use a non-GAAP tax rate of 40% to normalize the tax impact to our Non-GAAP Adjusted Net Income per Diluted Share based on the fact that a relatively small change in pre-tax GAAP income (loss) in any one period could result in a volatile GAAP effective tax rate.

Contact Info:
Dana Quattrochi
athenahealth, Inc. (Investors)
investorrelations@athenahealth.com
617-402-1329

Holly Spring
athenahealth, Inc. (Media)
media@athenahealth.com
617-402-1631